Stock Ratings / Health Care / CLDI / options

PMCB (40) CRIS (40) LIMN (45) SCNI (39) ⌘ Pro Terminal →

Calidi Biotherapeutics Inc. (CLDI) Options Positioning, Max Pain & Unusual Sweeps

Q: What is CLDI's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CLDI.

$0.67 -4.29% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.66

Calidi Biotherapeutics Inc. (CLDI) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.66 (-0.96%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLDI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY CLDI SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.03-18.4% Next Q

Q2 (-2Q)

Grade D$0.84-23.8% Next Q

Q3 (-1Q)

Grade D$0.64+4.7% Next Q

Current

Grade D-$0.67-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLDI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLDI currently carries a cautious 41/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.07) and Max Pain ($0.70) forces dealer call-delta covering toward $28.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLDI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CLDI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CLDI)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CLDI.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLDI)

✓Walkthrough of CLDI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLDI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -82.32%⚡ TESTING RESISTANCE

2026-10-30O $0.67H $0.69L $0.64C $0.67VOL 48.4K

RES: $0.88SUP: $0.53SMA50: $1.07SMA200: $4.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLDI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLDI Butterfly Map → + Track CLDI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLDI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLDI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLDI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLDI)

Health Care Rank #626 of 1016 ⚔️ PMCB vs CLDI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLDI vs. PMCB, CRIS, LIMN, SCNI)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Calidi Biotherapeutics Inc. (CLDI) ranks #626 by composite RQD confidence (41/100, grade D-) and #987 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, CLDI leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. LIMN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with CLDI at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLDI ACTIVE Calidi Biotherapeutics Inc.	D-	41/100	—	—	-35.0%	-4.29%	$2.5M	Benchmark Subject
PMCB PharmaCyte Biotech Inc.	D-	40/100	—	—	-30.2%	-0.78%	$3.6M	/pmcb-vs-cldi →
CRIS Curis Inc.	D-	40/100	—	—	-35.0%	+20.82%	$3.7M	/cris-vs-cldi →
LIMN Liminatus Pharma Inc. (Class A)	D	45/100	—	—	-35.0%	-0.86%	$3.9M	/limn-vs-cldi →
SCNI Scinai Immunotherapeutics Ltd.	D-	39/100	—	-30.0%	-35.0%	-2.92%	$1.4M	/scni-vs-cldi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001855485

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Calidi Biotherapeutics Inc. (CLDI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.9M, operating cash flow of -$21.3M, and free cash flow of -$21.3M (-8.1% YoY). On the balance sheet, CLDI closed FY2025 with $8.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$19.9M	-$21.3M	-$21.3M	$8.9M	—
FY2024 (FY)	2024-12-31	$0	-$22.1M	-$19.7M	-$19.7M	$14.2M	—
FY2023 (FY)	2023-12-31	$0	-$29.2M	-$27.0M	-$27.0M	—	—

3. CLDI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLDI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Calidi Biotherapeutics Inc. (NYSE: CLDI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.67 (-4.29% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CLDI ranks #626 in composite RQD confidence.

How does CLDI compare to PMCB and CRIS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CLDI carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMCB (PharmaCyte Biotech Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M) and CRIS (Curis Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M). Among the 5-stock peer group, CLDI leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLDI?

Per CLDI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855485), Calidi Biotherapeutics Inc. generated $0 in revenue, -$19.9M in net income, and -$21.3M in free cash flow against $8.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLDI trading relative to its 50-day, 200-day, and 52-week technical levels?

CLDI last traded at $0.67 (-4.29% on volume of 20,940 shares), positioning the stock -37.38% below its 50-day simple moving average ($1.07) and -84.91% below its 200-day simple moving average ($4.44). Across its 52-week range of $0.62 to $27.04, CLDI sits at the 0.2% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.75).

CLDI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CLDI's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CLDI.

Direct Sub-Reports: CLDI RQD Cockpit CLDI 12M Forecast CLDI Earnings & Move CLDI Dividends & DRIP CLDI Insiders & 13F CLDI Whale Options CLDI Profit Sankey CLDI News & Why